Generally speaking GLP1 analogues are extremely well tolerated drugs if they are started at low dosages and where increases in dosages occur at least a month apart
JBJS Case Connect
NEC can result in severe and permanent health complications, including intestinal perforation, digestive strictures, infections, cerebral palsy, neurological impairment, and even death
doi: 10.1152/physrev.00012.2022 19 CobourneMTIsekiSBirjandiAAAdel Al-LamiHThauvin-RobinetCXavierGMet al
Injectable Wegovy has demonstrated approximately 15% weight loss in clinical trials, while Eli Lillys Zepbounda dual GIP/GLP-1 agonistshows approximately 21% weight loss at its highest dose
however, the reported incidence varies widely from 1.5 up to 47% depending on the monitoring protocol (8, 10)